Three primary AML patient samples with FLT3 mutations showed a significant decrease in their colony-forming capacity following the combined treatment with AZD5991 and gilteritinib or MRX-2843 compared to the single-drug treatment and vehicle control (Figure 2A). This evidence concerns the gene FLT3 and acute myeloid leukemia.